Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with heterozygous familial hypercholesterolemia who were not adequately controlled with their lipid-modifying therapy~Exclusion criteria:~* Age \< 18 years or legal age of adulthood, whichever is greater~* LDL-C \< 70 mg/dL (1.81 mmol/L) and with cardiovascular disease~* LDL-C \< 100 mg/dL (2.59 mmol/L) and without cardiovascular disease~* Fasting serum triglycerides \> 400 mg/dL (4.52 mmol/L)~* Known history of homozygous familial hypercholesterolemia~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for alirocumab every 2 weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
- Alirocumab 75 mg/Up to 150 mg Q2W (Type: EXPERIMENTAL): Alirocumab 75 mg Q2W on top of stable LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when low-density lipoprotein cholesterol (LDL-C) levels ≥ 70 mg/dL (1.81 mmol/L) at Week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).